Supplementary Figure S6 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Supplementary Figure S6. Synergistic effect of DBPR728 in combination with PI3K/mTOR inhibitors. (A) Dose matrix of 6K465 in combination with copanlisib (a pan-PI3K inhibitor), alpelisib (a PI3Kalpha inhibitor) and idelalisib (a PI3Kdelta inhibitor) in NCI-H69 and NCI-H446 cells. Percent growth inhibition at each dose assessed at 72 hr after drug treatment was shown on the left. Synergy distribution based on a ZIP model was shown on the right. (B) Individual tumor growth curve of NCI-H69 and NCI-H446 xenografts in mice as presented in Fig. 6, C-D.